Literature DB >> 2997631

Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats.

S Arbilla, H Depoortere, P George, S Z Langer.   

Abstract

Zolpidem is a novel non-benzodiazepine related hypnotic, which possesses an imidazopyridine structure. This drug has preferential affinity for the 3H-diazepam binding site in the rat cerebellum, while it is only weakly active at inhibiting 3H-Ro 5-4864 binding to the rat kidney. The potency of zolpidem at displacing 3H-Ro 15-1788 binding to rat cerebral cortex membranes is enhanced in the presence of GABA. On the sleep pattern of the electrocorticogram in the curarised rat, zolpidem induces a physiological type of slow wave sleep with rapid onset of action. Zolpidem differs from classical benzodiazepine drugs, in possessing an atypical binding profile to 3H-benzodiazepine receptors, and because it does not affect the sleep patterns.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997631     DOI: 10.1007/bf00572441

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  Benzodiazepine receptors in rat brain.

Authors:  R F Squires; C Brastrup
Journal:  Nature       Date:  1977-04-21       Impact factor: 49.962

2.  Benzodiazepine receptor: demonstration in the central nervous system.

Authors:  H Möhler; T Okada
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

3.  Agonist and antagonist benzodiazepine receptor interaction in vitro.

Authors:  H Möhler; J G Richards
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Influence of GABA receptor agonists and antagonists on the binding of 3H-diazepam to the benzodiazepine receptor.

Authors:  M S Briley; S Z Langer
Journal:  Eur J Pharmacol       Date:  1978-11-01       Impact factor: 4.432

5.  Renal benzodiazepine binding increases during deoxycorticosterone/salt hypertension in rats.

Authors:  J W Regan; H I Yamamura; S Yamada; W R Roeske
Journal:  Eur J Pharmacol       Date:  1980-10-03       Impact factor: 4.432

6.  Stimulation of benzodiazepine receptor binding by gamma-aminobutyric acid.

Authors:  M Karobath; G Sperk
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Ethyl beta-carboline-3-carboxylate shows differential benzodiazepine receptor interaction.

Authors:  M Nielsen; C Braestrup
Journal:  Nature       Date:  1980-08-07       Impact factor: 49.962

8.  Interaction of convulsive ligands with benzodiazepine receptors.

Authors:  C Braestrup; R Schmiechen; G Neef; M Nielsen; E N Petersen
Journal:  Science       Date:  1982-06-11       Impact factor: 47.728

Review 9.  Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors.

Authors:  R F Squires; D I Benson; C Braestrup; J Coupet; C A Klepner; V Myers; B Beer
Journal:  Pharmacol Biochem Behav       Date:  1979-05       Impact factor: 3.533

10.  Some aspects of the polygraphic studies on sleep-wakefulness cycle in rat.

Authors:  H Depoortere
Journal:  Waking Sleeping       Date:  1980 Jan-Mar
View more
  25 in total

1.  Mechanism of action of the hypnotic zolpidem in vivo.

Authors:  F Crestani; J R Martin; H Möhler; U Rudolph
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 3.  Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective.

Authors:  D Wheatley
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

4.  Proceedings of the British Pharmacological Society. 6th-8th January, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

Review 5.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

6.  The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells.

Authors:  Josipa Vlainić; Maja Jazvinsćak Jembrek; Dubravka Svob Strac; Danka Pericić
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-23       Impact factor: 3.000

7.  Effect of the benzodiazepine receptor agonist, zolpidem, on palatable fluid consumption in the rat.

Authors:  K J Stanhope; S Roe; G Dawson; F Draper; A Jackson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  gamma-Aminobutyric acid type A receptor point mutation increases the affinity of compounds for the benzodiazepine site.

Authors:  D B Pritchett; P H Seeburg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 9.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

10.  Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat.

Authors:  Simon P Fisher; David Sugden
Journal:  Neurosci Lett       Date:  2009-04-07       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.